Maxis AI Introduces the First Verticalized Context Layer for Life Sciences, a Governed Execution Fabric That Makes Enterprise AI Reliable, Cost-Efficient, and Regulatory Compliant Maxis AI introduced MaxisAI Holarchy, its Verticalized Context Layer, a governed institutional memory that gives life sciences…
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai²…
Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City Cardio Diagnostics Holdings, Inc. an AI-driven precision cardiovascular medicine company, announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa.…
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a…
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, announced a collaboration and licensing agreement with Shenzhen CrystalO…
Greenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular Dystrophy Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, announced that it has received a Catalyze R61 award from the National…
New Multi-Center Study Shows equicenta® CTM, Ready-to-Use, Equine Umbilical Cord Allograft Outperforms Standard of Care in Returning Performance Horses to Work Equine Performance Labs (EPL), the team behind equicenta® CTM — announced the publication of a peer-reviewed, prospective, controlled clinical…
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the…
DXP Enterprises, Inc. Announces Acquisition of Mequipco Ltd. DXP Enterprises, Inc. announced that it has completed the acquisition of Mequipco Ltd. Founded in 1974, Mequipco is headquartered in Calgary, Alberta Canada and operates out of three locations servicing Western Canada including…
Neo7Bioscience & McCullough Foundation Expose 3.5-Year Spike Persistence, Cancer Genomic Integration & mRNA Gene Chaos — Personalized Precision Peptides Restore Critically Injured Patients Neo7Bioscience, a leader in aHI-driven personalized molecular solutions, announced compelling evidence of prolonged SARS-CoV-2 Spike protein persistence…
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases,…
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate Fresenius Kabi, an operating company of Fresenius, announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics…